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Abstract 
Excretion of albumin in urine, or albuminuria, is associated with the development of multiple cardiovascular 
and metabolic diseases. However, whether pathways leading to albuminuria are causal for cardiometabolic 
diseases is unclear. We addressed this question using a Mendelian randomization framework in the UK 
Biobank, a large population-based cohort. We first performed a genome-wide association study for 
albuminuria in 382,500 individuals and identified 32 new albuminuria loci. We constructed albuminuria 
genetic risk scores and tested for association with cardiometabolic diseases. Genetically-elevated 
albuminuria was strongly associated with increased risk of hypertension (1.38 OR; 95%CI, 1.27-1.50 per 
1-SD predicted increase in albuminuria, p = 7.01 x 10-14). We then examined bidirectional associations of 
albuminuria with blood pressure which suggested that genetically-elevated albuminuria led to higher blood 
pressure (2.16 mmHg systolic blood pressure; 95%CI, 1.51-2.82 per 1-SD predicted increase in 
albuminuria, p = 1.22 x 10-10), and that genetically-elevated blood pressure led to more albuminuria (0.005 
SD; 95%CI 0.004-0.006 per 1-mmHg predicted increase in systolic blood pressure, p = 2.45 x 10-13). These 
results support the existence of a feed-forward loop between albuminuria and blood pressure, and imply 
that albuminuria could increase risk of cardiovascular disease through blood pressure. Moreover, they 
suggest therapies that target albuminuria-increasing processes could have antihypertensive effects which 
are amplified through inhibition of this feed-forward loop. 
 
Introduction 
In observational epidemiologic studies, albuminuria, or the concentration of albumin excreted in urine, is 
associated with risk for multiple cardiometabolic diseases: elevations in albuminuria predict development 
of coronary artery disease, stroke, heart failure, type 2 diabetes, hypertension and all-cause mortality.1-9 
However, whether pathways leading to albuminuria are causally associated with cardiometabolic disease 
is unclear. Therapies lowering albuminuria are generally associated with reduced cardiovascular disease, 
for example. However, whether such effects are independent of concomitant reductions in blood pressure 
is ambiguous.10-14 Understanding whether associations of albuminuria pathways with disease reflect a 
  
causal relationship or mere correlation may inform whether targeting novel albuminuria-increasing 
processes could reduce risk for cardiometabolic diseases. 
 
‘Mendelian randomization’ can provide evidence regarding the hypothesis that a given biomarker-disease 
relationship is causal.15 The strengths and limitations of Mendelian randomization can be considered via 
analogy with a randomized clinical trial. Individuals are assigned to lifelong increase or decrease in a 
disease risk factor due to the random segregation and independent assortment of genetic polymorphisms 
at conception, thus minimizing two key limitations of observational epidemiology - reverse causation and 
confounding. The effect of genetically modifying an exposure (here, albuminuria) can then be tested against 
increasing or decreasing risk of an outcome (here, cardiometabolic disease). Three assumptions must be 
met in order for a genetic variant to be a potentially valid instrumental variable in Mendelian randomization: 
1) the variant must be strongly associated with the exposure; 2) the variant must not be associated with 
confounders; and 3) the variant must not be horizontally pleiotropic, i.e., cannot be associated with the 
outcome independent of the exposure pathway.16 While the second and third assumptions are hard to 
prove, many sensitivity analyses have been developed to improve the reliability of Mendelian randomization 
estimates.17 
 
Here, we first identify new genetic variants for albuminuria by conducting a genome-wide association study 
of albuminuria in 382,500 individuals in the UK Biobank. We subsequently utilized the identified genetic 
variants as instruments in a Mendelian randomization analysis to test the hypothesis that pathways 
increasing albuminuria are causal for cardiometabolic diseases.  
 
Subjects and Methods 
Study Design 
This study had three main components: first, we examined epidemiological associations of baseline 
albuminuria with incident cardiometabolic disease in UK Biobank. Second, we conducted a genome-wide 
association study of baseline albuminuria and constructed a polygenic risk score. Finally, we performed a 
  
Mendelian randomization study to test the hypothesis that the associations between processes leading to 
albuminuria and cardiometabolic diseases are causal.  
 
Study Participants 
UK Biobank 
Data from 382,500 unrelated individuals of European ancestry with albuminuria measurement in the UK 
Biobank were used. Samples were excluded for the following reasons: inferred sex did not match reported 
sex, kinship was not inferred, putative sex chromosome aneuploidy, consent withdrawn, or excessive 
heterozygosity or missingness, based on centralized sample quality control performed by UK Biobank.18 
Excluded related individuals were defined as one individual in each pair with KING coefficient > 0.0884, 
indicating 2nd degree or closer relatedness. European ancestry was determined by self-reported ancestry 
of British, Irish or Other White, followed by outlier detection using the R package aberrant with lambda = 40 
on genetic principal component (PC)1 and PC2, PC3 and PC4, and PC5 and PC6. Individuals who were 
outliers for any of the three pairs of PCs were removed from the European ancestry group. Kinship inference 
and genetic PCs were centrally calculated by UK Biobank.18  
 
Albuminuria and Blood Pressure 
Albuminuria was measured at the initial assessment visit (2006-2010); a Beckman Coulter AU5400 clinical 
chemistry analyzer was used to quantify urine albumin (df-30500, Randox Bioscience, UK; 
immunoturbidimetric assay, detection range 6.7 – 200 mg/L) and urine creatinine (df-30510, Beckman 
Coulter (UK), Ltd; enzymatic assay, detection range 88 – 44200 μmol/L) concentrations. Urine albumin 
concentrations below the lower limit of detection (df-30505, n=263654) were set to the lower limit of 
detection (6.7 mg/L). The resulting urine albumin:creatinine ratio (ACR, mg/g) was natural log-transformed 
to adjust for right skewedness. Microalbuminuria was defined as urine ACR of 25-355 mg/g in females and 
17- 250 mg/g in males; macroalbuminuria >355 mg/g in females and > 250 mg/g in males.19 Baseline blood 
pressure was averaged from two measurements taken a few moments apart using an Omron 705 IT 
electronic blood pressure monitor (df-4079 and df-4080). A sphygmomanometer (df-93 and df-94) was used 
  
if a measurement could not be obtained with the electronic monitor. 381,833 individuals had both blood 
pressure and albuminuria measurements. Albuminuria and blood pressure can both be decreased by 
hypertensive medication, but there is no consensus about the magnitude of such effects on albuminuria. 
Therefore, neither variable was corrected for hypertensive medication use so as not to selectively skew one 
variable but not the other.  
 
Disease Definitions 
Prevalent cardiometabolic diseases were defined at study entry through the electronic health record and/or 
self-report with confirmation via verbal interview by a trained nurse. Detailed definitions for all disease 
classifications can be found in Table S2. Incident cardiometabolic diseases were ascertained among those 
not meeting disease criteria at baseline by applying phenotype definitions to longitudinal, in-patient hospital 
and death registry data linked to the UK Biobank. Participants were censored at the time of disease 
diagnosis, date of death, or date of last follow-up (i.e., February 9, 2016 for participants enrolled in Wales, 
February 16, 2016 for participants enrolled in England, and October 31, 2015 for participants enrolled in 
Scotland), whichever occurred first. Participants were presumed alive at last follow-up if there was no 
preceding report of death in the death register. UK Biobank was approved by the Research Ethics 
Committee (reference 16/NW/0274) and informed consent was obtained from all participants. Analysis of 
UK Biobank data was approved by the Partners HealthCare institutional review board (protocol 
2013P001840). 
 
Atherosclerosis Risk in Communities (ARIC) 
10235 unrelated individuals in the Atherosclerosis Risk in Communities study, genotyped using the 
Affymetrix Genome-wide Human SNP Array 5.0, were imputed to the Haplotype Reference Consortium 
using the Michigan Imputation Server. Phasing was performed using the Eagle2 algorithm. 4954 variants 
were removed prior to imputation due to duplication, monomorphism or allele mismatch. Imputation was 
then performed on 799246 variants using the minimac3 algorithm. 39,235,157 variants in the Haplotype 
  
Reference Consortium were imputed. 6398 individuals were of European ancestry as confirmed by 
centrally-calculated, European-specific PC analysis and had albuminuria data.  
 
An untimed urine sample was collected during the visit 4 clinical examination. Aliquots were frozen within 
12 hours and stored at -70oC. Albumin and creatinine levels were measured in the University of Minnesota 
Physicians Outreach Laboratories, Minneapolis, Minnesota, with albumin by a nephelometric method either 
on the Dade Behring BN100 (assay sensitivity, 2.0 mg/L) or on the Beckman Image Nephelometer, and 
creatinine using the Jaffe method in order to determine the albumin-to-creatinine ratio (ACR; µg/mg) for 
participants. Blinded samples (n=516) analyzed for quality assurance showed a correlation coefficient (r) 
of the loge-transformed ACR as r=0.95. ACR was natural log-transformed for association analysis. 
Genotype and phenotype data were retrieved for analysis from NCBI dbGAP (phs000280.v3.p1) under 
procedures approved by the Partners HealthCare institutional review board (protocol 2016P002395). 
 
Framingham Heart Study 
8825 individuals from the Offspring and Third Generation cohorts of the Framingham Heart Study, 
genotyped using the Affymetrix GeneChip Human Mapping 500K Array, were imputed to the Haplotype 
Reference Consortium using the Michigan Imputation Server. Genetic PCs were calculated on directly-
genotyped data using EIGENSOFT v7.2.1 after removing variants with MAF < 0.01, genotype call rate < 
0.99 and samples with sample call rate < 0.97 using PLINK-1.9. PCs were calculated in unrelated 
individuals only based on self-reported pedigree, and projected onto related individuals. 6534 individuals 
were of self-reported white ancestry confirmed by PC analysis. PCs used as covariates for association tests 
were recalculated in the white subgroup, and 21 individuals were removed as outliers on the basis of this 
analysis. 6387 of the remaining individuals had albuminuria data available.  
 
Albuminuria was measured at Offspring Exam 8 and Third Generation Exam 1 visits at the Framingham 
Heart Study Laboratory using a Roche Hitachi 911 Chemistry Analyzer. Urine albumin was quantified by 
the immunoturbidometric Tina-quant Albumin test (assay sensitivity, 3.0 mg/L); urine creatinine by 
  
colorimetric, modified Jaffe (rate blanked) creatinine test (assay sensitivity, 0.2 mg/100ml). Urine albumin 
concentrations below the lower limit of detection (n=1682) were set to the lower limit of detection (3.0 mg/L). 
The resulting urine albumin:creatinine ratio (ACR, mg/g) was natural log-transformed for association 
analysis. Genotype and phenotype data were retrieved for analysis from NCBI dbGAP 
(phs000007.v26.p10) under procedures approved by the Partners HealthCare institutional review board 
(protocol 2016P002395). 
 
International Consortium for Blood Pressure 
The International Consortium for Blood Pressure is a large meta-analysis of study-specific results 
associating blood pressure with genotypes from the Cardio-MetaboChip SNP Array (nmax=201529)20 or 
imputed to 1000 Genomes Project Phase 1 haplotypes (nmax=150134).21 Summary statistics for SNP effects 
on systolic and diastolic blood pressure were corrected for anti-hypertensive medication use (+15 mmHg 
and +10 mmHg for systolic and diastolic blood pressure, respectively) and included body mass index, sex, 
age, age2 as covariates, as previously described.20,21 One limitation of this data set is that adjustment for 
body mass index and anti-hypertensive medication may lead to associations between genetic variants and 
adjusted blood pressure being confounded with other factors that influence the adjustment variables 
(“collider effects”). This could bias Mendelian randomization analyses with albuminuria, which is not 
adjusted for these factors.22 SNPs from the Cardio-MetaboChip study20 were used to construct blood 
pressure genetic risk scores, whereas association of albuminuria variants with blood pressure was 
examined using blood pressure effects measured in the 1000G-based study.21 
 
Statistical Analyses 
Observational Epidemiology 
In UK Biobank, Cox proportional hazards regression was used to determine the association of baseline 
albuminuria with incident cardiometabolic disease (average median follow-up time 7.0 years across 
diseases). Potential confounding variables were selected per prior epidemiological analyses of albuminuria 
and cardiometabolic disease,2,5,6,9,23-25 and a subsequent univariate screen of the selected traits in the UK 
  
Biobank was performed; these criteria yielded age at baseline, sex, current smoking status, body mass 
index, systolic blood pressure, diastolic blood pressure, baseline diabetes and baseline hyperlipidemia as 
covariates for inclusion in most Cox proportional hazard models. 
 
Genome-Wide Association Study 
UK Biobank samples were genotyped by Affymetrix using either the UK BiLEVE or UK Biobank Axiom 
arrays. Genotyped variants were then imputed by the UK Biobank central analysis team onto the Haplotype 
Reference Consortium reference panel.18 Variant exclusion criteria were Hardy-Weinberg equilibrium p ≤ 1 
x 10-20, QCTOOL INFOscore < 0.3, variant call rate ≤ 0.95 and MAF ≤ 0.001 yielding 11,709,857 variants 
in the analysis. Sex-specific residuals of natural log-transformed urine ACR were analyzed as a continuous 
trait with age, genotyping array, and the first 10 genetic PCs as covariates via least-squares linear 
regression under an additive effects model using Hail v0.1 statistical software (Web Resources).26 The 
threshold for statistical significance was empirically determined using permutation testing according to a 
previous approach.27 Association of chromosome 21 variants with 1000 random simulated continuous 
phenotypes were determined using Hail v0.1. The necessary significance threshold for a 5% family-wise 
error rate (FWER) was empirically estimated as the 5th percentile of the collection of the minimum variant 
p-value from each simulated phenotype. The corresponding number of independent tests on chromosome 
21 was calculated as p = 0.05/threshold5%FWER, and was scaled to genome-wide using the proportion of the 
11,709,857 genome-wide variants located on chromosome 21. This resulted in a genome-wide significance 
threshold of p < 9 x 10-9. Genomic inflation was calculated using the median estimator in the GenABEL 
package in R; LD score regression and common (MAF > 5%) SNP genetic correlation and heritability were 
calculated via LDSC v1.0.0 using standard variant filtering (MAF > 0.01 & INFOscore > 0.9), HapMap3 
SNPs and LD scores precomputed from European 1000 Genomes data.28 Variants were clumped into 
independent loci using PLINK-1.9 with R2 > 0.01 and <1 MB from the index variant (smallest p-value). 
 
Albuminuria Genetic Risk Score 
  
Up to forty-six SNPs independently associated with albuminuria at a conventional p < 5 x 10-8 threshold in 
the genome-wide association study (Table S4) were used to construct weighted polygenic risk scores using 
PLINK 2.00a2LM. Each imputed genotype dosage was multiplied by the effect of the SNP on natural log-
transformed urine ACR normalized to 1-SD albuminuria in UK Biobank (0.755 log(mg/g) urine ACR). The 
resulting weighted dosages were summed to create genetic risk scores. Association of the 46-SNP 
albuminuria genetic risk score with albuminuria in ARIC and Framingham Heart Study was determined 
using linear regression with age, sex and the first 10 genetic PCs as covariates. Sensitivity analysis 
excluding 1 and 10 poorly-imputed variants in ARIC and Framingham Heart Study, respectively, did not 
substantially affect association results. Variance explained by each score was calculated as the adjusted 
R2 from the association of albuminuria with the albuminuria genetic risk score, age, sex and 10 genetic PCs 
minus the adjusted R2 from the association of albuminuria with age, sex, and 10 genetic PCs.  
 
Blood Pressure Genetic Risk Scores 
Lead variants of genome-wide significant loci from Cardio-MetaboChip-based ICBP stage 4 meta-analysis20 
were used to construct systolic blood pressure and diastolic blood pressure genetic risk scores. These 
results did not include UK Biobank. Only variants significantly (p < 5 x 10-8) associated with a specific blood 
pressure trait were included in that trait’s score. rs10164833 was excluded from the systolic blood pressure 
risk score as it did not replicate in further ICBP meta-analysis. In UK Biobank, each imputed genotype 
dosage was multiplied by the effect of the SNP on mmHg systolic or diastolic blood pressures from ICBP 
stage 4 meta-analysis, which were corrected for hypertensive medication use and body mass index,20 and 
the resulting weighted dosages were summed. Variance explained by each score in UK Biobank was 
calculated as the adjusted R2 from the association of blood pressure corrected for hypertensive medication 
use with the blood pressure genetic risk score, age, sex and 10 genetic PCs minus the adjusted R2 from 
the association of blood pressure corrected for hypertensive medication use with age, sex, and 10 genetic 
PCs. 
 
Mendelian Randomization 
  
For individual-level data, association of the albuminuria or blood pressure genetic risk scores with outcomes 
were assessed using logistic (combined prevalent plus incident disease) or linear (continuous outcomes) 
two-stage least-squares regression in Stata v15. Age at baseline, sex, genotyping array and the first 10 
genetic PCs to control for population structure were included as covariates. For summary-level data, the 
analogous approach is an inverse-variance-weighted (IVW) fixed-effects meta-analysis of the effect of each 
SNP on the outcome divided by the effect of this SNP on albuminuria.29,30 Meta-analysis was conducted 
using the MendelianRandomization package31 in R. Effect estimates were normalized to 1-SD albuminuria 
in UK Biobank (0.755 log(mg/g) urine ACR). Power to detect associations with cardiometabolic disease in 
UK Biobank were calculated using an online tool (Web Resources, Table S13).  
 
Sensitivity Analyses 
We performed the following sensitivity analyses to address several limitations of Mendelian randomization: 
MR Steiger filtering to remove variants potentially acting through reverse causation,32,33 calculation of 
heterogeneity and random-effects IVW meta-analysis to allow for variant effect size heterogeneity (Tables 
S6-S10, S12),34,35 median regressions which allow up to 50% of information from variants to violate 
Mendelian randomization assumptions,36 MR-Egger regression to detect directional pleiotropy,37 Cook’s 
distance to detect extreme outliers,38 and unweighted allele scores to minimize bias from internally-derived 
weights in individual-level analyses.39  
 
MR Steiger Filtering 
The third assumption of Mendelian randomization (‘no association independent of the exposure’) requires 
that a variant acts first through the exposure and not the outcome. Observational studies suggest that 
diseases such as diabetes and hypertension can increase albuminuria.40,41 Some variants may therefore 
be associated with albuminuria via first increasing risk of such diseases and secondarily increasing 
albuminuria. These variants should not be included as instruments for testing the influence of albuminuria 
on those disease outcomes. 
 
  
The MR Steiger method strengthens evidence regarding whether a variant acts first through the exposure 
or outcome under a model of vertical pleiotropy, where the SNP associates with two traits because one trait 
influences the other. The correlation of a variant with an outcome is a product of both the variant-exposure 
correlation and the exposure-outcome correlation. The variant-exposure correlation should therefore be 
greater than the variant-outcome correlation.33 The MR Steiger method determines the variant-exposure 
and variant-outcome correlations, and removes variants where the variant-outcome correlation is greater 
than the variant-exposure correlation. The aim of this approach is to reduce the proportion of variants 
erroneously included in a Mendelian randomization analysis due to confounding or acting first through the 
outcome.32,33 We note that MR Steiger is not designed to distinguish between vertical pleiotropy and 
horizontal pleiotropy, wherein a SNP influences both traits through independent pathways.   
 
To perform MR Steiger filtering, the correlation of a variant with each exposure and outcome was first 
determined. For continuous traits from studies with individual-level data, the squared correlation of each 
variant with a continuous exposure or outcome was calculated as the R2 from association of the trait with 
the variant and covariates minus the R2 from association of the trait with covariates. For continuous traits 
from studies with summary statistics, the correlation R was estimated using get_r_from_pn in the 
TwoSampleMR package42 in R. Correlation R of each variant with binary traits was estimated on the logit 
liability scale33,43 using get_r_from_lor in TwoSampleMR modified to use allele frequency measured in UK 
Biobank. To apply directional MR Steiger filtering, variants with R2exposure < R2outcome were removed.  
 
As an additional sensitivity analysis for one-sample Mendelian randomizations with individual-level data, 
the Steiger test of correlated correlations was used to calculate the probability that the variant-exposure 
and variant-outcome correlations were different. Variants whose correlation with the exposure was not 
significantly different from correlation with the outcome, defined as Steiger p-value > 0.05, were removed. 
Steiger tests were calculated using the r.test in the psych package in R. This analysis was not performed 
for two-sample Mendelian randomizations, as correlations of a variant with an exposure or outcome from 
  
summary statistics are only estimated in separate cohorts and therefore may be less appropriate for 
detecting significant differences between the two measurements.  
 
Other Sensitivity Analyses 
IVW random-effects, simple median, weighted median and MR-Egger random-effects regression were 
calculated with normal distributions using the MendelianRandomization v0.2.0 package in R. For these 
analyses of individual-level data, associations of score SNPs with each outcome were determined via linear 
or logistic (Wald) regression using age at baseline, sex, genotyping array and the first 10 genetic PCs using 
Hail v0.1 statistical software. While MR-Egger can be particularly biased by weak instruments in individual-
level or one-sample Mendelian randomization analyses,44 the fact that MR-Egger regression results were 
roughly similar between one-sample and two-sample analyses (Tables S8 and S10) suggests that weak 
instrument bias is not disproportionately affecting these results. Graphs of each variant’s effect on exposure 
vs outcome and IVW-based leave-one-out analyses (Figures S2-S4, S6-S7) were created using the 
TwoSampleMR package in R. Variant effect heterogeneity was assessed via Cochran’s Q and MR-
PRESSO residual sum of squares (RSS), which shows improved false-positive rates.34 These were 
calculated using the MendelianRandomization and MRPRESSO34 v1.0 packages, respectively, in R. For 
outlier detection, Cook’s distance was calculated on IVW meta-analysis; SNPs with a Cook’s distance 
greater than twice the nominal outlier cutoff 4/nSNPs were considered for outlier exclusion. Unweighted allele 
scores were constructed by summing the number of albuminuria- or blood pressure-increasing alleles per 
individual. Two-stage least-squares regression was used to determine the association of the unweighted 
allele score with cardiometabolic outcomes as described above. Linkage disequilibrium between variants 
in albuminuria genetic risk scores and blood pressure genetic risk scores was defined as R2 > 0.2 and <1 
MB using linkage disequilibrium calculated in the UK Biobank study population via PLINK-1.9. 
 
Anti-hypertensive medications reduce albuminuria in addition to lowering blood pressure.45 We wanted to 
determine whether not correcting blood pressure and albuminuria for hypertensive medication use 
confounded albuminuria-blood pressure association results. As a sensitivity analysis, we therefore 
  
excluded individuals on hypertensive medication and re-tested association of an albuminuria genetic risk 
score with blood pressure. Hypertensive medication use was defined by self-report with confirmation via 
verbal interview by a trained nurse (df-6177 and df-6153). A genome-wide association study for albuminuria 
was performed in 302,687 individuals in UK Biobank not on hypertensive medication and who had blood 
pressure and albuminuria measurements. This yielded 23 independent loci (p < 5 x 10-8, R2 > 0.01 and <1 
MB from the index variant, Table S11). Effects of the 23 SNPs were used to construct an albuminuria risk 
score normalized to 1-SD albuminuria in this population (0.713 log (mg/g)). Associations of this albuminuria 
risk score with blood pressure were determined as above. Directional MR Steiger filtering removed one 
variant from the risk score for association with both systolic and diastolic blood pressure. 
 
Results 
382,500 unrelated individuals of European ancestry in the UK Biobank, a population-based cohort, were 
used in this study. 54% of participants were female, and the mean age was 56.9 (SD 7.9) years at baseline. 
Mean baseline systolic blood pressure and diastolic blood pressures were 138.3 (SD 18.6) and 82.3 (SD 
10.1) mmHg, respectively; 18940 (5.0%) individuals had diabetes at baseline and 53004 (13.9%) had 
hyperlipidemia at baseline. The median baseline urine albumin:creatinine ratio (ACR) was 9.8 mg/g (IQR 
6.1-16.5). 14.3% had microalbuminuria and 0.4% macroalbuminuria (Tables S1-S2). Baseline urine ACR 
was natural log-transformed and is referred to as albuminuria (mean 2.3, SD 0.755 log(mg/g)) in 
subsequent analyses.  
 
Association of Albuminuria with Development of Cardiometabolic Diseases 
In UK Biobank, we first examined the association of baseline albuminuria with risk of incident 
cardiometabolic diseases using Cox proportional hazard regression (average median follow-up time across 
all diseases, 7.0 years). Baseline albuminuria was strongly associated with subsequent development of 
cardiometabolic disease (Figure 1): a 1-SD increase in albuminuria was associated with higher hazard of 
all-cause mortality (1.22 HR; 95%CI 1.20-1.23), coronary artery disease (1.09 HR; 95%CI 1.07-1.11), stroke 
(1.16 HR; 95%CI 1.12-1.20), peripheral vascular disease (1.23 HR; 95%CI 1.19-1.27), heart failure (1.29 
  
HR; 95%CI 1.26-1.32), type 2 diabetes (1.20 HR; 95%CI 1.18-1.22), chronic kidney disease (1.51 HR; 
95%CI 1.48-1.54) and hypertension (1.22 HR; 95%CI 1.20-1.24) but not with other diseases such as skin 
cancer (1.00 HR; 95%CI 0.98-1.03), even after adjustment for standard metabolic risk factors. Thus, 
albuminuria measured in UK Biobank is associated with cardiometabolic disease in a manner consistent 
with previous observational studies.1,6,7,9,23  
 
Genome-wide Association Study for Albuminuria 
To identify variants to be used as genetic instruments for albuminuria, we conducted a discovery genome-
wide association study of albuminuria in the 382,500 UK Biobank participants. Minimal genomic inflation 
was observed (lambdaGC = 1.17, LD score regression intercept28 = 1.02, Figure S1). The common SNP 
heritability of albuminuria was 0.045 (SE 0.002). In addition to replicating the previously-reported46 
association at the CUBN locus (rs10795433: beta -0.024 log(mg/g) for C allele; p = 1.37 x 10-24), we 
discovered an additional 1247 genome-wide significant (p < 9 x 10-9) associations representing 32 novel 
independent loci, for a total of 33 genome-wide significant loci (Figure 2, Table 1). Novel associations of 
potential clinical interest include the NR3C2 and COL4A4 loci. NR3C2 encodes the mineralocorticoid 
receptor, and mineralocorticoid receptor antagonists such as spironolactone and eplerenone reduce 
albuminuria when added to other anti-hypertensive medications.47,48 Mutations in COL4A4 and neighboring 
gene COL4A3 can cause autosomal Alport Syndrome, which is characterized by kidney disease that can 
include proteinuria.49 22 of the 33 loci (or their proxies R2 > 0.8), were available in a smaller previously 
published genome-wide association study;46 of these, 20 had a consistent direction of effect and 7 were 
nominally significant (p < 0.05, Table S3).  
 
Albuminuria Genetic Instrument Strength 
A 46-SNP genetic risk score constructed from the 33 genome-wide significant loci plus an additional 13 loci 
meeting a conventional significance level of p < 5 x 10-8 (Table S4) explained 0.7% of the variance in 
albuminuria in UK Biobank (F-statistic, 2871). The genetic risk score was validated in two additional North 
American cohorts of European ancestry and non-inflated estimates were obtained. The 46-SNP score was 
  
associated with albuminuria in both the Atherosclerosis Risk in Communities study (n=6398, p = 6.7 x 10-
5, 0.2% variance in albuminuria explained) and the Framingham Heart Study (n=6387, p = 4.4 x 10-4, 0.2% 
variance in albuminuria explained; Table S5). 
 
Association of Albuminuria Genetic Risk Score with Cardiometabolic Disease 
We examined whether genetically-elevated albuminuria due to the 46-SNP risk score associated with 
increased risk of cardiometabolic disease in UK Biobank. Genetic predisposition to elevated albuminuria 
was associated with increased risk of hypertension (1.51 OR; 95%CI, 1.39-1.64 per 1-SD predicted 
increase in albuminuria due to the 46-SNP score, p = 2.68 x 10-22). However, no significant associations 
were observed between the albuminuria genetic risk score and risk of all-cause mortality, coronary artery 
disease, stroke, heart failure, type 2 diabetes, chronic kidney disease or skin cancer (Figure 3). 
 
To remove variants that may act through reverse causation – that is, influence albuminuria through 
hypertension – from the albuminuria score, we applied MR Steiger filtering.32,33 This approach removed 
three variants more directly associated with hypertension. After filtering, the 43-SNP score was still 
associated with increased risk of hypertension (1.38 OR; 95%CI, 1.27-1.50 per 1-SD predicted increase in 
albuminuria, p = 7.01 x 10-14, Figure 3). 
 
Bidirectional Mendelian Randomization of Albuminuria and Blood Pressure 
To further examine the association of albuminuria with hypertension, we investigated the genetic 
correlations between albuminuria, blood pressure and hypertension. We found significant common SNP 
genetic correlations between albuminuria and hypertension (rg = 0.16; SE 0.03, p = 2.06 x 10-8), systolic 
blood pressure (rg = 0.20; SE 0.03, p = 3.6 x 10-15) or diastolic blood pressure (rg = 0.10; SE 0.03, p = 3.2 
x 10-4). We performed bidirectional Mendelian randomization between albuminuria and blood pressure to 
understand the determinants of these correlations. First, we examined association of the albuminuria 
genetic risk score with blood pressure outcomes. After MR Steiger filtering, albuminuria genetic risk scores 
remained associated with increased systolic blood pressure (2.16 mmHg; 95%CI, 1.51-2.82 per 1-SD 
  
predicted increase in albuminuria, p = 1.22 x 10-10) and diastolic blood pressure (0.99 mmHg; 0.61-1.36 per 
1-SD predicted increase in albuminuria, p = 3.40 x 10-7, Figure 4). Next, we investigated the reverse 
association – blood pressure affecting albuminuria – using a blood pressure risk score as the exposure and 
albuminuria as the outcome. 47 and 52 variants significantly associated with blood pressure in ICBP,20 
which did not include UK Biobank, explained 1.2% and 1.4% of the variance in systolic and diastolic blood 
pressure, respectively, in UK Biobank. Both blood pressure risk scores were associated with elevated 
albuminuria (0.005 SD albuminuria; 95%CI 0.004-0.006 per 1 mmHg predicted increase in systolic blood 
pressure, p = 2.45 x 10-13 and 0.007 SD albuminuria; 95%CI 0.005-0.009 per 1 mmHg predicted increase 
in diastolic blood pressure, p = 1.83 x 10-9, Figure 4), validating a previous suggestive report.20 
 
Sensitivity Analyses 
Seven sets of sensitivity analyses were used to verify the robustness of the associations between 
albuminuria and hypertension or blood pressure. First, Mendelian randomization results were consistent for 
a restricted score at the genome-wide significance level of p < 9 x 10-9 (Table S6). Second, we used several 
methods to detect and mitigate the effects of pleiotropic variants: 1) MR Egger regression to detect the 
presence of directional pleiotropy;37 2) Cook’s distance to detect outlier variants, which can also indicate 
pleiotropy;38,50 3) leave-one-out analyses to determine if associations are biased by a single, potentially-
pleiotropic SNP;42 4) median-based regressions, which are robust when up to 50% of information comes 
from invalid variant instruments, including due to pleiotropy.36 Some directional pleiotropy was observed in 
the associations between albuminuria and blood pressure but not other associations (Tables S7-S9). MR-
Egger regression is especially sensitive to influential points,51,52 so the observed directional pleiotropy could 
be due in part to a potential outlier, rs141640975 in the CUBN locus (Cook’s distance = 0.6-0.7, Figures 
S2-S3). This variant was the top SNP in the albuminuria GWAS, raising the possibility that it could derive 
its large effect via aggregating potentially pleiotropic effects of multiple pathways. Excluding this variant 
reduced directional pleiotropy while maintaining associations between the albuminuria risk score and blood 
pressure or hypertension (Tables S7-9). Leave-one-out analyses suggested the observed associations 
were not biased by other single variants (Figures S2-S4, S6-S7). Notably, albuminuria risk scores also 
  
remained associated with hypertension and blood pressure, and blood pressure risk scores with 
albuminuria, using one or more forms of median regression that allow for many pleiotropic variants (Tables 
S7-S9).  
 
Third, to be more confident variants were not acting through reverse causation, we used a more stringent 
MR Steiger filter. This removed variants that were not significantly more associated with albuminuria than 
outcomes. While effect estimates were slightly attenuated, the associations of albuminuria with blood 
pressure and hypertension persisted even after this additional filtering (Tables S7-S8).  
 
Fourth, for bidirectional Mendelian randomization it is important that variants in the albuminuria score are 
not in linkage disequilibrium with variants in the blood pressure score.22 One pair of variants at the HOTTIP 
locus was in linkage disequilibrium (rs2023844-rs3735533 R2 = 0.99). MR Steiger analysis suggests this 
variant is more directly associated with blood pressure. It was therefore removed from all albuminuria risk 
scores by directional MR Steiger filtering. Additionally, sensitivity analyses excluding this variant from blood 
pressure risk scores did not affect association of blood pressure risk scores with albuminuria (Table S9).   
 
Fifth, using the same samples for both discovery of a genetic risk score and analysis of score effects can 
bias association results towards the observational estimate.53 Unweighted genetic risk scores can reduce 
this bias.39 Unweighted albuminuria risk scores were also associated with increased risk of hypertension 
and elevated systolic and diastolic blood pressure in UK Biobank (Tables S7-S8). 
 
Sixth, to further mitigate bias from score discovery-analysis overlap in UK Biobank, we examined the effects 
of albuminuria-associated variants on blood pressure measured in a separate cohort. Blood pressure 
effects in ICBP were corrected for hypertensive medication use.21 In this cohort, albuminuria variants were 
associated with increased systolic blood pressure (2.69 mmHg; 95%CI, 1.18-4.19 per 1-SD predicted 
increase in albuminuria, p = 4.64 x 10-4) and nominally with increased diastolic blood pressure (1.03 mmHg; 
0.10-1.97 per 1-SD predicted increase in albuminuria, p = 0.030, Figures S5-S6, Table S10).  
  
 
Finally, hypertensive medications lower both albuminuria and blood pressure. To investigate this source of 
potential bias, we excluded any individuals in UK Biobank taking hypertensive medication. The effects of 
the resulting albuminuria genetic risk score on increased blood pressure were largely consistent (Figures 
S5 & S7, Tables S11-S12) albeit with reduced power in this n=302,687 subset.     
 
Discussion 
We used Mendelian randomization to examine if processes leading to elevated albuminuria lead to 
increased risk of cardiometabolic disease. A genome-wide association study of albuminuria in UK Biobank 
identified 32 new albuminuria loci. A genetic risk score of up to 46 albuminuria variants was strongly 
associated with increased risk of hypertension and elevated blood pressure, but showed only weak 
associations with other cardiometabolic diseases.  
 
These results permit several conclusions. First, processes that increase albuminuria appear to increase 
risk of hypertension and blood pressure. Although hypertension is commonly thought to increase 
albuminuria, previous epidemiological studies also suggest that albuminuria predicts development of 
hypertension.7,8 Our data add genetic and observational evidence supporting this association. Multiple 
pathways leading to albuminuria may contribute to hypertension. Albuminuria may arise as a result of 
generalized endothelial dysfunction,54-56 which can contribute to development of hypertension.57,58 
Albuminuria can also result from kidney damage. In damaged kidneys, increased blood pressure is thought 
to help the subfunctional kidney excrete sufficient sodium to maintain sodium homeostasis.59,60 Consistent 
with this, severe kidney injury leads to experimental hypertension61 and mild kidney damage precedes the 
development of hypertension in multiple experimental models.59,62 The intrinsic role of the kidney in blood 
pressure regulation is also supported by the observation that kidney transplantation from hypertensive 
donors can cause hypertension in previously normotensive recipients.63,64 Further work is needed to 
determine the mechanisms via which risk score variants contribute to elevated albuminuria.  
 
  
Second, application of MR Steiger filtering32,33 enabled the discovery of evidence for bidirectional effects 
between albuminuria and blood pressure. The associations of genetically-elevated albuminuria with 
increased blood pressure, and of genetically-elevated blood pressure with increased albuminuria, suggest 
that the relationship between albuminuria and blood pressure is bidirectional. This would imply the 
existence of a feed-forward loop, in which elevated blood pressure leads to increased albuminuria, which 
in turn would further increase blood pressure. It is important to note that because each Mendelian 
randomization analysis estimates the effects in one direction, this feedback loop is not formally modelled 
by such analyses.53 These results suggest that therapies targeting processes that lower albuminuria could 
have antihypertensive effects that are further amplified by inhibiting this feed-forward loop. Determining the 
specific genes and pathways affected by albuminuria variants could assist in rational design of such 
therapies. 
 
Third, these results imply that processes leading to albuminuria can influence cardiovascular disease 
through blood pressure. Observational and genetic evidence establishes blood pressure as an important 
causal risk factor for multiple cardiovascular diseases.20,65-67 By the principal of two-step Mendelian 
randomization,16,68 significant associations between an albuminuria risk score and blood pressure, and 
between blood pressure risk scores and diseases such as stroke or coronary artery disease,20 imply that 
the albuminuria risk score is associated with these diseases at least via blood pressure. This raises the 
question of why we did not observe significant associations between albuminuria and such diseases. 
Stronger genetic risk scores may be necessary to detect downstream consequences of a causal 
relationship between albuminuria and blood pressure: since blood pressure explains only some of the 
variance in cardiovascular outcomes,69 albuminuria should have a smaller effect size on cardiovascular 
disease than on blood pressure. We therefore may have been underpowered to detect such downstream 
effects of albuminuria-induced hypertension on cardiovascular diseases (Table S13). Larger data sets that 
generate stronger albuminuria genetic risk scores should help clarify this issue. 
 
  
A key strength of this study is that albuminuria and genotypes were measured in 382,500 individuals, seven 
times more than the next largest genome-wide association study,46 enabling construction of a polygenic 
risk score that explained 0.2% of the variance in albuminuria in two validation cohorts. We were also able 
to validate the associations between albuminuria and blood pressure in an outside cohort. Access to 
individual-level data in UK Biobank allowed us to interrogate whether these associations were confounded 
by hypertensive medication use. Finally, we used MR Steiger filtering to remove variants that potentially 
acted through reverse causation, and multiple sensitivity analyses to detect and mitigate pleiotropic 
variants.  
 
Several limitations should be acknowledged. First, reliance on internally-derived weights in our albuminuria 
genetic risk score may have biased our results towards the observational associations.44 To address this, 
we replicated significant associations using unweighted allele scores and/or in two-sample analyses. 
Second, an alternate explanation for the bidirectional associations observed is that a shared genetic basis 
underlies the two traits. If so, SNPs that influence both traits through a shared mechanism could violate the 
instrument strength independent of direct effect (InSIDE) assumption of standard Mendelian randomization 
and MR-Egger analyses.70 Although the associations were consistent using median-based regressions, 
which do not require the InSIDE assumption,36,42 we cannot rule out the possibility that associations 
between albuminuria and blood pressure are due to a shared genetic basis of the two traits rather than 
causal effects. Third, there was substantial heterogeneity in the causal effect estimates from different 
variants (Tables S6-S10, S12); i.e., for association of albuminuria variants with hypertension, Cochran’s Q 
= 160 (p = 9.5 x 10-16). This is perhaps not surprising considering the hypothesis under investigation was 
whether pathways that lead to albuminuria can increase blood pressure and hypertension risk. It is plausible 
– and quite likely – that multiple albuminuria-inducing pathways exist which could elevate blood pressure 
to different degrees (i.e., endothelial dysfunction and kidney damage), or not at all (i.e., pathways involved 
in albumin metabolism or post-renal urine regulation).51 However, other sources of heterogeneity could 
nevertheless be present, although these do not necessarily lead to bias.17,51 Fourth, UK Biobank is a 
population-based longitudinal cohort. Our study was likely underpowered to detect associations in diseases 
  
less common than hypertension (Table S13); therefore, lack of association of albuminuria with other 
diseases should not be over-interpreted. Finally, it is important to note that UK Biobank is an older cohort 
of European ancestry; therefore, results may differ in younger populations or in other ethnic backgrounds.  
 
In conclusion, an albuminuria genetic risk score of up to 46 SNPs was associated with increased risk of 
hypertension and elevated blood pressure. Application of recently-developed Mendelian randomization 
methods identified evidence of bidirectional effects from albuminuria-increasing pathways to blood 
pressure, and from blood pressure to albuminuria. These results provide genetic data to refine and highlight 
the complex interplay between albuminuria and hypertension. 
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Figure Titles and Legends 
Figure 1. Association of albuminuria with incident disease endpoints in UK Biobank.  
Incident disease aadjusted for age, sex, current smoking status, body mass index, systolic blood pressure, 
diastolic blood pressure, baseline diabetes and baseline hyperlipidemia unless otherwise specified. 
badjusted for age, sex, current smoking status, body mass index, systolic blood pressure, diastolic blood 
pressure, waist-to-hip ratio and baseline hyperlipidemia. cadjusted for age, age2, current smoking status, 
body mass index, baseline diabetes and baseline hyperlipidemia. Bars indicate 95% confidence interval for 
hazard ratio.   
 
Figure 2. Genome-wide association study of albuminuria in UK Biobank identifies 32 new loci.  
33 genome-wide significant loci are indicated by red points. Red line indicates genome-wide significance 
threshold (p = 9 x 10-9); blue line indicates conventional significance threshold (p = 5 x 10-8).  
 
Figure 3. Association of genetic predisposition to increased albuminuria with risk of 
cardiometabolic disease in UK Biobank.  
Two-stage least-squares regression using albuminuria genetic risk score as instrumental variable; age, sex, 
genotyping array and 1st 10 genetic PCs as covariates. Results are standardized to 1-SD increase in 
albuminuria due to the genetic risk score. A, genetic risk score composed of all 46 albuminuria variants. B, 
genetic risk score composed of 43 albuminuria variants after applying directional MR Steiger filtering to 
remove variants potentially acting in the incorrect direction. Bars indicate 95% confidence interval for odds 
ratio. 
 
Figure 4. Bidirectional Mendelian randomization identifies suggestive causal effects of albuminuria 
on blood pressure, and of blood pressure on albuminuria.  
A, Mendelian randomization of albuminuria genetic risk scores on blood pressure in UK Biobank 
(n=381833). Two-stage least-squares regression using albuminuria genetic risk score as instrumental 
variable on blood pressure outcome; age, sex, genotyping array and 1st 10 genetic PCs as covariates. 
  
Results are standardized to 1-SD increase in albuminuria due to the genetic risk score. Genetic risk scores 
were composed of 44 albuminuria variants after applying directional MR Steiger filtering to remove variants 
potentially acting in the incorrect direction.  
B, Mendelian randomization of blood pressure genetic risk scores on albuminuria. Effects of variants on 
systolic or diastolic blood pressure were determined in ICBP20 (nmax=201529) and thus corrected for 
hypertensive medication use and adjusted for body mass index. Two-stage least-squares regression using 
blood pressure genetic risk score as instrumental variable on albuminuria outcome in UK Biobank 
(n=381833); age, sex, genotyping array and 1st 10 genetic PCs as covariates. Results are standardized to 
1-mmHg increase in blood pressure due to the genetic risk score. 47 or 52 variants were used to construct 
scores specific for systolic or diastolic blood pressure, respectively. Directional MR Steiger filtering removed 
no variants.  
SNPs in score, number of SNPs remaining after directional MR Steiger filtering applied. Bars indicate 
95% confidence interval for effect on blood pressure (top) or albuminuria (bottom).  
  
Tables 
 
Lead variant Nearest Gene(s) Description Chr 
Position 
(hg19) 
Effect 
Allele 
Noneffect 
Allele EAF 
Beta 
(log(mg/g)) 
SE 
(log 
(mg/g)) P value 
rs12032996 PHC2-ZSCAN20 Intergenic 1 33920586 G A 0.838 0.01463 0.00226 9.33E-11 
rs10157710 FOXD2-TRABD2B Intergenic 1 47961691 T C 0.802 0.01900 0.00209 9.69E-20 
rs11264327 EFNA3-EFNA1 Intergenic 1 155095107 A G 0.399 0.00987 0.00171 7.03E-09 
rs4665972 SNX17 Intronic 2 27598097 T C 0.393 0.01176 0.00172 6.96E-12 
rs13394343 SH2D6-
MAT2A/PARTICL 
Intergenic 2 85754342 C A 0.570 0.01053 0.00168 3.86E-10 
rs10207567 ICA1L Intronic 2 203714973 C G 0.813 0.01455 0.00214 1.00E-11 
rs1047891 CPS1 Missense 2 211540507 C A 0.684 0.01205 0.00179 1.71E-11 
rs183131780 MIR548AR-LOC646736 Intergenic 2 226684886 T C 0.002 0.19055 0.01959 2.33E-22 
rs35483183 COL4A4 Intronic 2 227876687 A G 0.123 0.01490 0.00255 5.19E-09 
rs35924503 SPHKAP-PID1 Intergenic 2 229131286 C T 0.001 0.24742 0.02518 8.68E-23 
rs112607182 PRKCI Downstream 
Variant 
3 170027407 T C 0.077 0.02279 0.00327 3.39E-12 
rs7654754 SHROOM3 Intronic 4 77409795 G A 0.462 0.01020 0.00167 9.96E-10 
rs6535594 NR3C2 Intronic 4 149132756 A G 0.496 0.01146 0.00167 7.12E-12 
rs189107782 LINC01262-FRG1 Intergenic 4 190729009 T C 0.002 0.24502 0.02026 1.12E-33 
rs702634 ARL15 Intronic 5 53271420 A G 0.692 0.01042 0.00181 8.03E-09 
rs7731168 CWC27 Intronic 5 64296471 C G 0.233 0.01253 0.00197 2.19E-10 
rs4410790 AGR3-AHR Intergenic 7 17284577 C T 0.634 0.01798 0.00173 2.63E-25 
rs2023844 HOTTIP Intronic 7 27243238 A G 0.926 0.01934 0.00318 1.18E-09 
rs17158386 WIPF3-DPY19L2P3 Intergenic 7 29805361 A G 0.262 0.01330 0.00191 3.65E-12 
rs28601761 TRIB1-LINC00861 Intergenic 8 126500031 C G 0.579 0.01136 0.00171 2.81E-11 
rs45551835 CUBN Missense 10 16932384 A G 0.014 0.14237 0.00698 2.28E-92 
rs144360241 CUBN Missense 10 16967417 C T 0.005 0.08186 0.01234 3.31E-11 
rs1276720 CUBN Intronic 10 16971426 T C 0.745 0.01109 0.00193 8.98E-09 
rs141640975 CUBN Missense 10 16992011 A G 0.003 0.35876 0.01629 1.75E-107 
rs67339103 C10orf11 Intronic 10 77893686 A G 0.212 0.01522 0.00205 1.07E-13 
rs17368443 SBF2 Intronic 11 10296836 C G 0.061 0.02071 0.00348 2.58E-09 
rs2601006 CCT2 5' UTR Variant 12 69979517 C T 0.657 0.01176 0.00176 2.13E-11 
rs4288924 ZFP36L1-ACTN1 Intergenic 14 69302399 G A 0.480 0.00980 0.00168 5.66E-09 
rs8035855 MAPKBP1 Intronic 15 42077961 A G 0.644 0.01227 0.00174 1.91E-12 
rs1145074 SPATA5L1 Intronic 15 45703824 T A 0.745 0.01140 0.00191 2.41E-09 
rs2472297 CYP1A2-CYP1A1 Intergenic 15 75027880 T C 0.267 0.01812 0.00188 5.31E-22 
rs35572189 BAHCC1 Missense 17 79419025 G A 0.638 0.01051 0.00174 1.44E-09 
rs838142 FUT1 3' UTR Variant 19 49252151 A G 0.723 0.01174 0.00187 3.13E-10 
Table 1. Albuminuria loci from GWAS of 382,500 individuals in UK Biobank.  
Chr, chromosome; EAF, effect allele frequency. For intergenic loci, nearest upstream and downstream 
RefSeq genes are indicated. Nearest gene should not be taken as evidence of causal gene. Description, 
most-severe consequence of nearest RefSeq gene. 
